CD44 overexpression related to lymph node metastasis and poor prognosis of pancreatic cancer
CD44 overexpression related to lymph node metastasis and poor prognosis of pancreatic cancer
复制标题
DOI：
10.1177/1724600817746951
复制
发表时间：
2018-08-01
影响因子：
2
通讯作者：
Zhang, Lin
中科院分区：
文献类型：
--
作者：
Liu, Yijuan;Wu, Ting;Zhang, Lin
背景：CD44最近被报道为胰腺癌的一种生物标志物。然而，CD44在胰腺癌中的预测价值仍存在争议。因此，我们进行了这项荟萃分析，以评估CD44表达与胰腺癌患者临床病理特征和预后之间的关系。材料和方法：使用PubMed， Embase和中国国家知识基础设施进行全面的文献检索。采用Stata软件进行统计分析。结果：本meta分析共纳入9项研究，共583例。荟萃分析显示，CD44过表达与较差的5年总生存率（OR 0.52; 95% CI 0.30, 0.91; P = 0.02）、更多的淋巴结侵袭(OR 3.14（阳性对阴性）；95% ci 1.47, 6.73；P = 0.003)，更晚期的T期(OR 2.4 (T3,4 vs. T1,2)；95% ci 1.28, 4.52；P = 0.007)，更晚期的TNM (OR 4.53 （III与IV相似vs. I与II相似）；95% ci 1.46, 14.08；P = 0.01)。然而，CD44过表达与肿瘤大小、分化和远处转移等其他临床病理特征无关。结论：目前的证据表明CD44在胰腺癌中是一个有效的预后因子。
Background: CD44 has recently been reported as a biomarker for pancreatic cancer. However, the predictive value of CD44 in pancreatic cancer remains controversial. Therefore, we performed this meta-analysis to evaluate the association between the expression of CD44 and clinicopathological features, and the outcome of pancreatic cancer patients.Materials and method: A comprehensive literature search was performed using PubMed, Embase, and Chinese National Knowledge Infrastructure. The statistical analysis was conducted using Stata software.Results: A total of nine studies including 583 cases were included in this meta-analysis. The meta-analysis indicated that CD44 overexpression was associated with poor five-year overall survival rate (OR 0.52; 95% CI 0.30, 0.91; P = 0.02), more lymph node invasion (OR 3.14 (positive vs. negative); 95% CI 1.47, 6.73; P = 0.003), more advanced T stage (OR 2.4 (T3,4 vs. T1,2); 95% CI 1.28, 4.52; P = 0.007), and more advanced TNM stage (OR 4.53 (III similar to IV vs. I similar to II); 95% CI 1.46, 14.08; P = 0.01). However, CD44 overexpression was not associated with other clinicopathological features, such as tumor size, differentiation, and distance metastasis.Conclusions: The current evidence suggests that CD44 is an efficient prognostic factor in pancreatic cancer.